Skip to content
Search jobs inside your AI agent. Claude, ChatGPT, Gemini, Cursor and Grok
Connect

Avenzo Therapeutics

Developing next-generation oncology therapies for cancer patients.

biotechpharmaceuticals

Company facts

Founded
2022
Employees
125
Headquarters
United States
CEO
Athena Countouriotis
Type
Private
Funding
Series B · $60M · 2025

About

Avenzo Therapeutics is a clinical-stage biotechnology company focused on developing next-generation oncology therapies for patients. The company was co-founded in 2022 by Dr. Athena Countouriotis and Dr. Mohammad Hirmand, former CEO and CMO of Turning Point Therapeutics respectively. Headquartered in San Diego, California, Avenzo is dedicated to improving the lives of people diagnosed with cancer by delivering therapies that improve upon today's standard of care. The company is advancing a pipeline of potentially differentiated targeted oncology programs, including CDK2 and CDK4 inhibitors for hormone receptor-positive breast cancer, as well as bispecific antibody-drug conjugates targeting EGFR/HER3 and Nectin4/TROP2 for various solid tumors. Avenzo's approach leverages deep expertise in oncology drug development, with the resources, knowledge, and determination to advance drug candidates that address cancers with high unmet medical needs. The company has raised significant funding, including a $150 million oversubscribed Series A round and a $60 million Series B financing, demonstrating strong investor confidence in their mission and pipeline.

Open positions

11 jobs